Drugs / LMP776
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01051635 | Jan 2010 → Jun 2017 | lymphoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LMP776 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01051635 ↗ |
| Known as | NSC 725776 | “LMP400 (NSC 743400) and LMP776 (NSC 725776) are indenoisoquinolines that have not been given to cancer patients before.” NCT01051635 ↗ |
| Route | Intravenous | “LMP776 administered IV daily for 5 days per dose escalation table.” NCT01051635 ↗ |